Limits...
α-Methylacyl-CoA racemase (AMACR) serves as a prognostic biomarker for the early recurrence/metastasis of HCC.

Xu B, Cai Z, Zeng Y, Chen L, Du X, Huang A, Liu X, Liu J - J. Clin. Pathol. (2014)

Bottom Line: Some important clinical parameters such as α-fetoprotein, tumour numbers, dissemination to regional lymph nodes, tumour capsule and portal vein tumour thrombosis are significantly associated with the low expression of AMACR.The median survival time was 17 months in the low-expression group compared with 45 months in the high-expression group.This study reveals that the AMACR might be a potential prognostic marker for predicting early recurrence/metastasis of HCC after hepatectomy.

View Article: PubMed Central - PubMed

Affiliation: Liver Disease Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou, People's Republic of China The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, People's Republic of China The Liver Center of Fujian Province, Fujian Medical University, Fuzhou, People's Republic of China.

Show MeSH

Related in: MedlinePlus

Kaplan–Meier's analysis of the correlation between the α-methylacyl-CoA racemase (AMACR) expression and the survival of hepatocellular carcinoma (HCC) patients. Patients with HCC with low-expression level of AMACR (n=95) had significantly lower survival rate than those with high-expression level of AMACR (n=63), (p<0.001).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4215266&req=5

JCLINPATH2014202378F2: Kaplan–Meier's analysis of the correlation between the α-methylacyl-CoA racemase (AMACR) expression and the survival of hepatocellular carcinoma (HCC) patients. Patients with HCC with low-expression level of AMACR (n=95) had significantly lower survival rate than those with high-expression level of AMACR (n=63), (p<0.001).

Mentions: The associations between the expression level of AMACR and postoperative clinical features have been further studied and shown in table 3. The AMACR expression has been assessed in 158 patients, including 101 cases of early recurrence/metastasis (R/M≤12 months), 21 cases of late recurrence/metastasis (R/M12–24 months) and 36 cases of none-recurrence/metastasis (NR/M). As shown in table 4, the low expression of AMACR was detected in 12 cases of NR/M HCC patients (in a total of 36 patients, the low-expression rate was 33.3%). In contrast, the AMACR low-expression rate was significantly higher in the early recurrence/metastasis group (R/M≤12 months, 71 of 101, low-expression rate 70.3%, p<0.001). Meanwhile, the patients with low expression of AMACR had very discouraging prognosis, only with a median survival of 17 months; however, the patients with high expression of AMACR had a better prognosis, with a median survival of 45 months (figure 2).


α-Methylacyl-CoA racemase (AMACR) serves as a prognostic biomarker for the early recurrence/metastasis of HCC.

Xu B, Cai Z, Zeng Y, Chen L, Du X, Huang A, Liu X, Liu J - J. Clin. Pathol. (2014)

Kaplan–Meier's analysis of the correlation between the α-methylacyl-CoA racemase (AMACR) expression and the survival of hepatocellular carcinoma (HCC) patients. Patients with HCC with low-expression level of AMACR (n=95) had significantly lower survival rate than those with high-expression level of AMACR (n=63), (p<0.001).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4215266&req=5

JCLINPATH2014202378F2: Kaplan–Meier's analysis of the correlation between the α-methylacyl-CoA racemase (AMACR) expression and the survival of hepatocellular carcinoma (HCC) patients. Patients with HCC with low-expression level of AMACR (n=95) had significantly lower survival rate than those with high-expression level of AMACR (n=63), (p<0.001).
Mentions: The associations between the expression level of AMACR and postoperative clinical features have been further studied and shown in table 3. The AMACR expression has been assessed in 158 patients, including 101 cases of early recurrence/metastasis (R/M≤12 months), 21 cases of late recurrence/metastasis (R/M12–24 months) and 36 cases of none-recurrence/metastasis (NR/M). As shown in table 4, the low expression of AMACR was detected in 12 cases of NR/M HCC patients (in a total of 36 patients, the low-expression rate was 33.3%). In contrast, the AMACR low-expression rate was significantly higher in the early recurrence/metastasis group (R/M≤12 months, 71 of 101, low-expression rate 70.3%, p<0.001). Meanwhile, the patients with low expression of AMACR had very discouraging prognosis, only with a median survival of 17 months; however, the patients with high expression of AMACR had a better prognosis, with a median survival of 45 months (figure 2).

Bottom Line: Some important clinical parameters such as α-fetoprotein, tumour numbers, dissemination to regional lymph nodes, tumour capsule and portal vein tumour thrombosis are significantly associated with the low expression of AMACR.The median survival time was 17 months in the low-expression group compared with 45 months in the high-expression group.This study reveals that the AMACR might be a potential prognostic marker for predicting early recurrence/metastasis of HCC after hepatectomy.

View Article: PubMed Central - PubMed

Affiliation: Liver Disease Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou, People's Republic of China The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, People's Republic of China The Liver Center of Fujian Province, Fujian Medical University, Fuzhou, People's Republic of China.

Show MeSH
Related in: MedlinePlus